Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EMN 2018 | Combatting oral mucositis with cryotherapy after high dose melphalan

Monika Engelhardt • 19 Apr 2018
EMN 2018
General Multiple Myeloma Melphalan

Monika Engelhardt, MD, of the University Medical Center Freiburg, Freiburg, Germany, discusses a promising study conducted at her center using oral cryotherapy to prevent mucositis in patients treated with high dose melphalan chemotherapy. This video was recorded at the 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy.

More from Monika Engelhardt

Tackling underrepresentation of minorities in CAR-T clinical trials for multiple myeloma 1:48
Tackling underrepresentation of minorities in CAR-T clinical trials for multiple myeloma
Monika Engelhardt • 16 Apr 2024
Improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma 2:06
Improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma
Monika Engelhardt • 16 Apr 2024
Achieving functional cure in transplant-eligible and transplant-ineligible multiple myeloma 2:53
Achieving functional cure in transplant-eligible and transplant-ineligible multiple myeloma
Monika Engelhardt • 16 Apr 2024
Emerging therapeutic challenges to treating patients with multiple myeloma 2:05
Emerging therapeutic challenges to treating patients with multiple myeloma
Monika Engelhardt • 16 Apr 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals